Key result
Repeated p-chlorophenylalanine lowers arterial pressure ~10% but fails to prevent neurogenic hypertension.
Answers are grounded in this paper and cite their sources.
SUMMARY 1. Intraperitoneal administration of p-chlorophenylalanine (pCPA: 100–400 mg/kg per day) reduced central serotonin concentrations to 20–50% of control in the rabbit. 2. Intraperitoneal administration of a single dose of pCPA (400 mg/kg) decreased heart rate by 14% for a period of 1–2 days, but did not affect arterial pressure. 3. Repeated intraperitoneal administration of pCPA (100 mg/kg per day) caused a gradual reduction in arterial pressure to about 90% of control values over a 10 day period, but had no consistent effect on heart rate. 4. In rabbits that received repeated intraperitoneal injections of pCPA (100 mg/kg per day), the tachycardia that followed sinoaortic denervation was not as well sustained as in normal rabbits; the development of neurogenic hypertension was unaltered. 5. Intracisternal administration of pCPA was particularly toxic in the rabbit; the maximum doses tolerated did not succeed in lowering central serotonin concentration and had no effect on blood pressure or heart rate.
No takes yet. Share an insight, caveat, or question.
Wing et al. (1974) studied Neurogenic hypertension. p-chlorophenylalanine (pCPA) vs. Control (normal rabbits) was evaluated on Blood pressure and heart rate. Repeated intraperitoneal p-chlorophenylalanine (100 mg/kg/day) reduced arterial pressure to ~90% of control over 10 days without preventing neurogenic hypertension in rabbits.
Synapse has enriched 10 related papers. Consider them for comparative context: